SCHEMBL30983536

SCHEMBL30983536

C[C@H](c1cc(Cl)ccn1)n1c(-c2ccc(OCCN3CCNCC3)cc2Cl)nc2c(OC3(C)CC3)ncnc21

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PDE2A O00408 1/20 0.38
▸ DRD2 P14416 7/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ HRH4 Q9H3N8 5/20 0.35
▸ PRKAB2 O43741 1/20 0.34
▸ PRKAG1 P54619 1/20 0.34
▸ PRKAA2 P54646 1/20 0.34
▸ PRKAA1 Q13131 1/20 0.34
▸ PRKAG3 Q9UGI9 1/20 0.34
▸ PRKAG2 Q9UGJ0 1/20 0.34
▸ PRKAB1 Q9Y478 1/20 0.34
▸ ALK Q9UM73 1/20 0.32
▸ ESR1 P03372 2/20 0.31
▸ ESR2 Q92731 2/20 0.31
▸ CNR1 P21554 2/20 0.31
▸ CNR2 P34972 1/20 0.31
▸ GPR55 Q9Y2T6 1/20 0.31
▸ KCNH2 Q12809 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30983568 1.00 PDE2A (0.38) PDE2ADRD2KDM4EALDH1A1HRH4
SCHEMBL30983442 1.00 PDE2A (0.38) PDE2ADRD2KDM4EALDH1A1HRH4
SCHEMBL30984048 0.86 PDE2A (0.38) PDE2ADRD2KDM4EALDH1A1HRH4
SCHEMBL30983570 0.85 PDE2A (0.39) PDE2ADRD2KDM4EALDH1A1HRH4
SCHEMBL30983612 0.85 PDE2A (0.39) PDE2ADRD2KDM4EALDH1A1HRH4
SCHEMBL30983543 0.85 PDE2A (0.39) PDE2ADRD2KDM4EALDH1A1HRH4
SCHEMBL30983467 0.82 PDE2A (0.38) PDE2ADRD2KDM4EALDH1A1HRH4
SCHEMBL31268922 0.82 PDE2A (0.36) PDE2ADRD2KDM4EALDH1A1HRH4
SCHEMBL30983378 0.82 HTR6 (0.41) PDE2ADRD2KDM4EALDH1A1HRH4
SCHEMBL31269004 0.82 PDE2A (0.38) PDE2ADRD2KDM4EALDH1A1HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP claimed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO claimed
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
US-12414954-B2 POLQ inhibitors ASTRAZENECA AB (SE) 2025-09-16 — — US disclosed
US-20250195530-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2025-06-19 — — US disclosed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 — — US disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366615-A1 POLQ INHIBITORS POLQ, POLG, POLB PDE2A 1118/4885DRD2 3087/4885KDM4E 2215/4885
US-12414954-B2 POLQ inhibitors POLQ, POLG, POLB PDE2A 1118/4885DRD2 3087/4885KDM4E 2215/4885
US-20250195530-A1 POLQ INHIBITORS POLQ, POLG, POLB PDE2A 1118/4885DRD2 3087/4885KDM4E 2215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback